ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO155

14-3-3ζ Targets β-Catenin Nuclear Translocation to Maintain Mitochondrial Homeostasis, Promoting Balance of Proliferation and Apoptosis in Cisplatin-Induced AKI

Session Information

  • AKI: Mechanisms - III
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Sun, Zhaoxing, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
  • Ding, Xiaoqiang, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
  • Yu, Xiaofang, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

Cisplatin, an extensively used chemotherapeutic agent for solid tumors, is limited in clinical use due to its side effects, especially nephrotoxicity. Cisplatin-induced acute kidney injury (AKI) is characterized by DNA damage, cell cycle arrest and mitochondrial oxidative stress. Recent work demonstrated that 14-3-3ζ plays important role in cancers, nerve disease and kidney disease, but the role and regulatory mechanism in cisplatin AKI remain to be further clarified.


Here, we found that 14-3-3ζ mRNA was upregulated in human kidney organoids (GSE145085) when treated with cisplatin, which was confirmed in experimental mice. Then, we used inhibitor for 14-3-3 (BV02) in animal experiment, knocking down and overexpressing 14-3-3ζ respectively in vitro experiments to test the role of 14-3-3ζ in cisplatin-induced AKI.


The use of protein interaction inhibitor for 14-3-3 (BV02) aggregated drop of renal function, apoptosis, mitochondrial dysfunction and oxidative stress in cisplatin-induced AKI. Accordingly, increased apoptosis, cell cycle arrest, ROS production and lipid dysbolism in cisplatin-treated NRK-52E cells were exacerbated in cells knocking down 14-3-3ζ. Besides, blocking 14-3-3ζ both in vivo and in vitro suppressed β-catenin and its nuclear translocation, downregulating the expression of downstream gene cyclin D1 in cisplatin-induced damage. In contrast, overexpression of 14-3-3ζ relieved injury caused by cisplatin and promoted nuclear transportation of β-catenin. Further, a non-specific agonist of β-catenin BIO reversed the effects of knocking down 14-3-3ζ in cisplatin-induced damage in NRK-52E by activating β-catenin. The direct interaction between 14-3-3ζ and β-catenin was then verified.


Taken together, these findings indicate that 14-3-3ζ protects against cisplatin-induced AKI by improving mitochondrial function and balance of proliferation and apoptosis through facilitating β-catenin nuclear translocation.


  • Government Support – Non-U.S.